Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2024.05.023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Patrick Squires und 6 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co, Inc, Rahway, NJ. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Protein Kinase Inhibitors. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: While covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL), response duration is limited and resistance to BTKi and/or adverse events develop in a subset of patients. However, little real-world evidence on post-cBTKi clinical and economic outcomes exists for these patients. PATIENTS AND METHODS: This retrospective study used 2010 to 2019 U.S. Medicare claims, to identify elderly (≥ 66 years) patients with newly-diagnosed MCL who received third-line (3L) treatment and had evidence of cBTKi use in a prior line of therapy. Outcomes were assessed ≥ 12-months post 3L-treatment initiation and included treatment patterns, all-cause and MCL-related HRU and costs, and overall survival. RESULTS: The final sample contained 230 elderly patients with R/R MCL receiving 3L treatment who had cBTKi use in a prior line of therapy (mean age 75.0, 21.7% age > 80 years; 67.4% male; 93.9% White). Common 3L treatments included chemotherapy (26.1%), lenalidomide (18.7%), and bortezomib (18.3%); 1-quarter (25.7%) of patients received a cBTKi (17.8% ibrutinib; 7.8% acalabrutinib). Overall survival was poor from 3L treatment initiation (median OS = 9.4 months; 1-years survival rate = 43.7%). Patients exhibited high rates of HRU (73.6% experienced hospitalization) and substantial costs ($145,726) in the 12-months after 3L initiation. CONCLUSION: A large unmet need exists in this patient subpopulation, highlighting the importance of ongoing development of novel therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck & Co, Inc, Rahway, NJ.
- COVIA Health Solutions, Lansdale, PA. Electronic address: justin@coviahealthsolutions.com.
- COVIA Health Solutions, Lansdale, PA. Electronic address: sachin@coviahealthsolutions.com.
- Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
- Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT.
Zitieren
APA
Squires, P., Puckett, J., Ryland, K. E., Kamal-Bahl, S., Raut, M., Doshi, J., & Huntington, S. F. (2024). Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.05.023
Vancouver
Squires P, Puckett J, Ryland KE, Kamal-Bahl S, Raut M, Doshi J, et al. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.05.023
BibTeX
@article{Squires2024,
author = {Squires, Patrick and Puckett, Justin and Ryland, Katherine Elizabeth and Kamal-Bahl, Sachin and Raut, Monika and Doshi, Jalpa and Huntington, Scott F},
title = {Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2024.05.023}
}
EUVIMED